Dr Erika Hamilton

Go Back

Breast Cancer and Gynecologic Cancer Research Program

  • Sarah Cannon Research Institute (SCRI)
  • location United States

Dr Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship.  She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in oncology at Duke University. She joined Sarah Cannon Research Institute as investigator in drug development for women’s cancers in 2013. Since 2015 she has served as the Director of the Breast and Gynecologic Cancer Research Program.  She sees patients facing breast cancer from standard of care to phase II/III to phase I drug development. Dr Hamilton was named to the Women to Watch Class of 2021 for Nashville Medical News. She serves on the board for local Susan G. Komen. She was selected for ASCO’s Leadership Development Class for 2021-2022, the past Chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020, and currently serves on ASCO’s Cancer Research Committee, the 2023-2025 Scientific Committee Co-Chair of the ESMO Breast Cancer Meeting and is on the Scientific Committee for AACR for 2023. She serves an Associate Editor for Clinical Breast Cancer.

Dr Erika Hamilton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Dr Hamilton discloses research funding (payable to institution only, no personal funds) from : OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millenium, Acerta Pharma, Sermonix Pharmaceuticals, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, FujiFilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, SeaGen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, Abbvie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, Amgen, Akesobio Australia, Shattuck Labs

D. Hamilton discloses consulting/advisory role payments( to institution only, no personal funds accepted) from: Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, AstraZeneca, Arvinas, Deciphera Pharmaceuticals, Eisai, Seagen